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SUMMARY
Objective: Antiepileptic drug (AED) treatment failures may occur because there is
insufficient drug in the brain or because of a lack of relevant therapeutic response.
Until now it has not been possible tomeasure these factors. It has been recently shown
that the combination of transcranial magnetic stimulation and electroencephalogra-
phy (TMS-EEG) can measure the effects of drugs in healthy volunteers. TMS-evoked
EEG potentials (TEPs) comprise a series of positive and negative deflections that can
be specifically modulated by drugs with a well-known mode of action targeting inhibi-
tory neurotransmission. Therefore, we hypothesized that TMS-EEG can detect effects
of twowidely used AEDs, lamotrigine and levetiracetam, in healthy volunteers.
Methods: Fifteen healthy subjects participated in a pseudo-randomized, placebo-con-
trolled, double-blind, crossover design, using a single oral dose of lamotrigine (300 mg)
and levetiracetam (3,000 mg). TEPs were recorded before and 120 min after drug
intake, and the effects of drugs on the amplitudes of TEP components were statistically
evaluated.
Results: A nonparametric cluster-based permutation analysis of TEP amplitudes
showed that AEDs both increased the amplitude of the negative potential at 45 msec
after stimulation (N45) and suppressed the positive peak at 180 msec (P180). This is
the first demonstration of AED-inducedmodulation of TMS-EEGmeasures.
Significance: Despite the differentmechanism of action that lamotrigine and levetirac-
etam exert at themolecular level, both AEDs impact the TMS-EEG response in a simi-
lar way. These TMS-EEG fingerprints observed in healthy subjects are candidate
predictive markers of treatment response in patients on monotherapy with lamotrig-
ine and levetiracetam.
KEYWORDS: Electroencephalography, Epilepsy, Pharmaco-TMS-EEG, Antiepileptic
drug, Transcranial magnetic stimulation.
Antiepileptic drugs (AEDs) are widely used for the
treatment of epilepsy and sometimes used to treat other
conditions such as migraine and bipolar disorder. It is
assumed that they act to reduce neural firing, epileptic
synchronization, and seizure spread.1 Some AEDs sup-
press neural membrane excitability by blocking voltage-
dependent Na+/Ca2+ channels; others increase c-amino
butyric acid (GABA)–mediated inhibitory neurotransmis-
sion, or antagonize excitatory glutamate neurotransmis-
sion.1 Despite the wide range of mechanisms of action,
epileptic seizures are refractory to AEDs in 30% of cases.2
An inadequate response to AEDs may occur because the
drug does not enter or remain in the brain, or because it
does not exert a sufficient pharmacologic response. Until
now, neither of these factors has been directly measure-
able, and the reason for treatment failure is therefore usu-
ally unknown. Thus, it would be an important step
forward to directly measure the pharmacologic effect of
AEDs in the human brain.
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FULL-LENGTHORIGINALRESEARCH
Transcranial magnetic stimulation combined with elec-
tromyography (TMS-EMG) has been used to characterize
the effect of AEDs in the brain and the relationship between
these effects and therapeutic response in patients.3 For
instance, the TMS parameter named resting motor threshold
(RMT) was associated with ion channel conductivity as it
was increased after the administration of AEDs targeting
Na+ channels.4 Furthermore, an important clinical study in
patients with new-onset epilepsy showed an association
between an increase of RMT values soon after commence-
ment of first AED treatment and long-term seizure control.5
However, these TMS-EMG measures are not used clini-
cally, and markers for AED responsiveness are still lacking.
To increase the power of TMS as a tool to directly investi-
gate the brain, TMS has been combined with electroen-
cephalography (TMS-EEG).6 It has been shown recently
that TMS-EEG is a successful tool to directly measure the
activity of drugs in the brain in healthy volunteers.7,8 The
complex EEG response to single-pulse TMS stimulation is a
sequence of positive and negative peaks at specific latencies
(i.e., P25, N45, P70, N100, and P180), named TMS-evoked
EEG potentials (TEPs). TEPs have been analyzed before
and after the administration of drugs with a well-known
mechanism of action on inhibitory GABAergic neurotrans-
mission. Results showed that the N45 and N100 potentials
are associated with GABAA and GABAB receptor–
mediated inhibition, respectively.7
Recently, TMS-EEG has been used to assess abnormal
cortical excitability patterns in epilepsy populations.
Patients with Unverricht-Lundborg–type progressive myo-
clonus epilepsy showed an increase of the early positive
waveform and suppression of late components.9 In contrast,
patients with juvenile myoclonic epilepsy were found to
have increased N100 and P180 amplitude after sleep depri-
vation.10 Finally, patients with epilepsy from periventricu-
lar nodular heterotopias showed abnormal TMS-EEG
activity at late latencies in line with findings from patients
with focal epilepsy.11,12 However, patients included in these
studies were receiving AED treatment, which could per se
alter the morphology of TEPs.
Here, we investigated TMS-EEG effects of two of the
most prescribed AEDs, lamotrigine and levetiracetam,13 in
healthy volunteers. The TEP signatures of AED activity in
normal subjects may provide candidate biomarkers of treat-
ment response, which should be validated in future clinical
studies. In addition, we believe that our findings will add
new insight on the neurophysiologic origin of TEPs, which
could be used in the future to identify the mechanism of
action of newly discovered drugs.
Materials and Methods
Subjects
Fifteen male subjects aged 19–34 years (mean age  s-
tandard deviation [SD] 25.2  4.62 years) were recruited
to the study from a local research volunteer database. One
subject only was not able to complete the TMS-EEG
recording after the intake of lamotrigine; therefore, the
total number of subjects for this condition is fourteen.
Female participants were excluded due to evidence of men-
strual cycle–related effects on cortical excitability, which
could introduce a confound.14 All the subject were right-
handed according to the Edinburgh Handedness Inventory
(laterality score ≥ 75%).15 Before the experiment, subjects
underwent a physical examination and checked for any
contraindications to TMS. Exclusion criteria included the
use of central nervous system (CNS) active drug, abuse of
any kind of drugs (nicotine/alcohol included), contraindi-
cations to the study medications (levetiracetam/lamotrig-
ine) and a history of psychiatric or neurologic disease. The
experimental protocol was approved by King’s College
London Research Ethics Committee, and all the
participants gave their written informed consent before the
experiment.
Experimental design
A pseudo-randomized, placebo-controlled, double-
blinded crossover study was used to assess the acute effects
of a single oral dose of the AEDs lamotrigine (300 mg) and
levetiracetam (3,000 mg) on TEPs. These doses were used
because they are effective standard daily doses for epilepsy
treatment and in previous reports they have been effective
in altering TMS measures of motor cortical excitabil-
ity.16–19 Lamotrigine is a voltage-gated Na+ channel
blocker, whereas levetiracetam acts primarily by binding to
synaptic vesicle protein 2A (SV2A), modulating its actions
to affect neuronal excitability and exerting seizure protec-
tion through effects on synaptic transmission.1 Subjects par-
ticipated in three sessions spaced 1 week apart to exclude
crossover effects and drug interference. The experimental
protocol is described in Figure 1. First, RMT was measured
predrug intake; next, TEPs were recorded before and
120 min after drug intake with 100% RMT predrug as
intensity of stimulation. Drug-induced changes of RMT
were also measured. The timing of postdrug measurement
was chosen according to drug pharmacokinetics and to pre-
vious studies reporting a significant alteration of motor
Key Points
• TMS-EEG is a noninvasive in vivo method to measure
the effects of drugs acting in the human brain
• Lamotrigine and levetiracetam modulate the TMS-
evoked EEG response to a similar extent irrespective
of their molecular target
• These TMS-EEG fingerprints may indicate candidate
predictive markers of treatment response in patients
on monotherapy with lamotrigine and levetiracetam
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cortical excitability at this time point.16–18,20 A blood sam-
ple was taken 5 min before commencement of postdrug
measurement to check drug plasma levels. Finally, 2 h after
drug intake, subjects were asked to rate their level of seda-
tion on an ordinal scale from 0 to 3, with 0 = no, 1 = mild,
2 = moderate, and 3 = severe sedation.19
Transcranial magnetic stimulation (TMS) and
electromyography (EMG)
Using a figure-of-eight coil (external diameter of each
wing, 90 mm) connected to a Magstim 2002 magnetic
stimulator (Magstim) with a monophasic current wave-
form, focal TMS of the hand area of the left primary motor
cortex (M1) was performed. The optimal coil position to
elicit motor evoked potentials (MEPs) in the first dorsal
interosseous (FDI) muscle of the right hand was deter-
mined as the site where TMS consistently generated stable
responses with amplitudes of ~1 mV. The hotspot position
and the edge of each coil’s wing were marked on top of the
EEG cap using a felt tip pen. In addition, the same experi-
menter conducted all the TMS-EEG sessions for each par-
ticipant and study session. Coil position and orientation
relative to the marked position were monitored carefully
by the experimenter throughout stimulation and corrected
if necessary (i.e., if the participant moved). MEP record-
ings were obtained by surface EMG using Ag-AgCl cup
electrodes in a belly-tendon montage. The coil was held
tangentially over the scalp with the handle pointing back-
ward and about 45 degrees away from the midsagittal line.
This orientation induces current flow in the lateral-poster-
ior to medial-anterior direction, activating the corticospinal
system transsynaptically via horizontal corticocortical con-
nections, and is optimal for eliciting MEPs.21
Single TMS pulses were applied to determine the RMT
using the relative frequency method.22 This was defined as
the lowest stimulus intensity sufficient to elicit an MEP of
>50 lV peak-to-peak amplitude in at least 5 of 10 trials
while the FDI muscle was relaxed.
Transcranial magnetic stimulation (TMS) and
electroencephalography (EEG)
A TMS-compatible EEG system was used to record
TMS-evoked EEG potentials (TEPs) (BrainAmp MRplus;
Brain Products), which prevented EEG amplifier saturation
and allowed continuous data recording throughout TMS.
The EEG signal, digitized at a frequency of 5,000 Hz, was
acquired continuously from 64 sintered Ag/AgCl electrodes
(EasyCap 64Ch; Brain Products), with the impedance kept
below 10 kΏ throughout the experiment. Subjects were on a
comfortable reclined chair and asked to stay awake with
their eyes open and focusing on a fixation cross, and they
were asked to minimize eye blinks and other movements
during the recording blocks. Earphones with a masking
noise were used to avoid contamination of the EEG signal
by auditory potentials induced by the click associated with
the TMS coil sending pulses.23
Before and after drug intake, 150 pulses were delivered at
an intensity of 100% RMT over the left M1 FDI hotspot,
with a 4 s interstimulus interval and a variance of 20% to
avoid adaptation (Fig. 1).
TMS-EEG data processing and analysis
After excluding trials with prominent eye movements,
blinks, and muscle artifacts (on the basis of visual inspec-
tion), EEG data were analyzed using a MATLAB toolbox
(FieldTrip, http://fieldtrip.fcdonders.nl/)24 following a mul-
tistep procedure.7 EEG data were downsampled to 1 kHz,
segmented 1 s before and after the pulse, and a linear inter-
polation for10 msec was applied to remove the TMS arti-
fact. Bad channels (mean number  SD per subject
3  0.5) were removed from the EEG, and the signal was
reconstructed by interpolating the surrounding electrode
signals. Data was then re-referenced to the linked mastoids
(TP9 and TP10 electrodes), notched filtered (50 Hz), and
detrended. Residual artifacts related to the TMS pulse (e.g.,
TMS recharging artifact, muscle decay artifact), eye-blinks,
saccades, and muscle movement were removed by
Figure 1.
Experimental protocol and timeline. RMT and TMS-EEG sessions were recorded before and 120 min after drug intake. Stimulation inten-
sity during TMS-EEG postdrug was set at 100% predrug RMT. Five minutes before postdrug measurement a blood sample was taken for
each subject to verify drug plasma concentration.
Epilepsia ILAE
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independent component analysis (FastICA).25 Components
were removed on the basis of the spatiotemporal profile
indicating the activation of temporal muscles, and by an
activation of opposed polarity mainly recorded over fronto-
central electrodes.25–27 Finally, remaining data were base-
line corrected (from600 to100 ms) and a low pass filter
was applied (45 Hz).
TEPs were calculated by averaging artifact-free EEG tri-
als (averaged number of trials across subjects before and
after levetiracetam: 116  14 and 98  21; lamotrigine:
119  14 and 104  21; and placebo: 114  21 and
111  11). Specifically, five TEPs components (P = Posi-
tive, N = Negative) in accordance with the literature7,28
were studied: P25 (time of interest, TOI [15–35 msec]),
N45 (36–65 msec), P70 (65–90 msec), N100 (90–
145 msec), and P180 (145–300 msec). TOIs were chosen
on the basis of the grand-averaged TEPs and kept identical
during the analysis of predrug and postdrug measurements
and across conditions. To analyze drug-induced modulation
of TMS-evoked potentials, we selected a region of interest
(ROI) that was composed of 12 channels over and around
the stimulation site (left M1) and the corresponding con-
tralateral site (FC1, FC3, FC5, C1, C3, C5, CP1, CP3, CP5,
P5, P3, P1, FC2, FC4, FC6, C2, C4, C6, CP2, CP4, CP6, P2,
P4, and P6).
Statistics
To evaluate drug effects on RMT, a repeated-measures
analysis of variance (ANOVA) was performed with drug
(three levels: levetiracetam, lamotrigine, placebo) and time
(two levels: predrug, postdrug) as within-subject factors.
To analyze significance of TEP amplitude modulations
induced by lamotrigine and levetiracetam, multiple depen-
dent sample t-test comparisons (postdrug vs. predrug and
between drug conditions) were applied for each TOI in all
the electrodes within the indicated ROI. To correct for mul-
tiple comparisons (i.e., electrodes, time points), we con-
ducted a nonparametric cluster-based permutation
analysis29 as implemented in FieldTrip. In particular, a
paired t-test was conducted for each electrode at each time
bin within the specified TOIs. T-values exceeding an a pri-
ori threshold of p < 0.05 were clustered based on adjacent
time bins and neighboring electrodes. Cluster-level statis-
tics were calculated by taking the sum of the t-values within
every cluster. The statistical comparisons were done with
respect to the maximum values of summed t-values. By
means of a permutation test (i.e., randomizing data across
conditions and rerunning the statistical test 1,500 times), we
obtained a reference distribution of the maximum of
summed cluster t-values to evaluate the statistic of the
actual data. Clusters in the original dataset were considered
to be significant at an alpha level of 5% if <5% of the per-
mutations (N = 1,500) used to construct the reference dis-
tribution yielded a maximum cluster-level statistic larger
than the cluster-level value observed in the original data.
Possible relations between the AED-induced sedation,
AED blood concentrations, and changes in TEPs were
explored by applying Spearman correlation analysis.
Results
All the subjects, except for one, tolerated the experimen-
tal protocol and the study medications. The common side
effects were sedation, drowsiness, and dizziness, but these
did not prevent the completion of the experiment. In ratings
of sedation level for each condition (0 = no sedation,
1 = mild sedation, 2 = moderate sedation, and 3 = severe
sedation), the average of all participants for the placebo was
0.4  0.6 (n = 15), levetiracetam was 1.5  0.9 (n = 15),
and lamotrigine was 1.1  0.8 (n = 14). A Friedman test
indicated a significant effect of drug (v22 = 11.4,
p = 0.003). Averaged plasma concentration for levetirac-
etam was 57.4  8.6 mg/L (reference range 6.0–20.0 mg/
L) and for lamotrigine was 4.1  0.8 mg/L (reference
range 1.0–15.0 mg/L).
Antiepileptic drug effects on TMS-evoked EEG
potentials
Repeated-measures ANOVA of RMT data showed a sig-
nificant main effect of time (F1,14 = 43.6, p < 0.001) and
drug (F2,28 = 4.5, p = 0.02). In line with previous reports,
there was a significant interaction between TIME and
DRUG (F2,28 = 13.6, p < 0.001), which was explained by a
significant increase of RMT after intake of levetiracetam
(p = 0.002) and lamotrigine (p < 0.001), whereas placebo
had no effect on RMT (p > 0.05).4,18 Finally, there were no
significant differences between predrug RMT values, which
were used as stimulation intensity for predrug and postdrug
TMS-EEG blocks (Fig. 1) (levetiracetam: 52.5  6.7%
maximum stimulator output [MSO]; lamotrigine:
51.7  6.9% MSO; placebo: 51.8  7.4% MSO;
F1,14 = 0.65, p > 0.05).
The averaged EEG response after single-pulse TMS of
M1 at baseline showed typical TEP components (P25, N45,
P70, N100, and P180) as previously found in literature.7,28
The topography shows that P25 and P180 were positive and
located respectively in central and contralateral site with
respect to the left M1, whereas the N45, P70, and the N100
were located predominately in the ipsilateral hemisphere
but spreading also over contralateral sites (Fig. 2). The clus-
ter analysis did not show significant effects (p > 0.05)
between the predrug conditions, showing high reproducibil-
ity across sessions.
The cluster-based permutation analysis was applied
between postdrug and predrug conditions to test the effect
of AEDs on TEPs. Although placebo did not show any sig-
nificant changes, levetiracetam and lamotrigine increased
the amplitude of the N45 potential in channels close to
the stimulation (pre-levetiracetam: 2.73  1.26 lV
[n = 15]; post-levetiracetam: 4.55  2.56 lV [n = 15],
Epilepsia, **(*):1–9, 2016
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p < 0.001, channels levetiracetam: FC1, FC3, FC5, C1, C3,
C5, CP1, CP3, CP5, P1, P3, and P5; pre-lamotrigine:
3.06  1.51 lV [n = 14]; post-lamotrigine: 4.00 
1.63 lV [n = 14], p = 0.01, channel lamotrigine: C3, C5,
CP1, CP3, CP5, P3, and P5; Fig. 3A–C) and suppressed the
P180 amplitude over channels contralateral to the stimu-
lated area (pre-levetiracetam: 6.26  3.21 lV [n = 15];
post-levetiracetam: 4.56  1.82 lV [n = 15], p = 0.03,
channel levetiracetam: FC2, C2, CP2, C4, and CP4; pre-
lamotrigine: 5.11  2.45 lV [n = 14]; post-lamotrigine:
3.80  2.15 lV [n = 14]; and p = 0.02, channel lamotrig-
ine: FC4, C2, C4, C6, CP2, CP4, and P2; Fig. 3B–D).
These results were confirmed by the comparison of post-
drug conditions. Compared to placebo, levetiracetam and
lamotrigine increased the N45 component over channels
ipsilateral to stimulation (levetiracetam channels: FC1,
FC5, C1, C3, C5, and P3, p < 0.001; lamotrigine channels
CP3, CP5, and P3, p = 0.01) and suppressed the P180 (leve-
tiracetam channels: FC4, C4, and C6, p = 0.03; lamotrigine
channels: C3, FC3, and FC5, p = 0.03). Furthermore, leve-
tiracetam only suppressed the N100 potential over contralat-
eral sites (channels: FC2, FC4, FC6, C6, and C4, p = 0.03).
Finally the comparison between levetiracetam and lamotrig-
ine did not show significant differences (p > 0.05 for all the
TOIs). These results may suggest that these AEDs with dif-
ferent mechanisms of action could provoke similar modula-
tion of TMS-EEG activity.
We investigated the AED-induced changes of the N45
and P180 components at the level of individual subjects.
Although most of the subjects revealed an enhancement of
the N45 and suppression of the P180 potentials after leve-
tiracetam and lamotrigine intake, a few participants showed
opposite trend (Fig. 4).
Correlations
We explored possible relations between AED-induced
modulation of TEPs and drug plasma concentration as well
as drug-induced level of sedation. The correlation analyses
were not significant (p > 0.05), suggesting that TEP
changes are not related to the amount of drug in the blood or
to sedation.
Discussion
We utilized TMS-EEG to obtain cortical signatures of
two widely used AEDs in healthy participants. Despite the
different molecular targets, we found that both lamotrigine
and levetiracetam modulated TEPs in a similar trend. At
group level, they significantly increased the N45 potential
and decreased the amplitude of later components. These
results are reflected at the individual level; however, a few
subjects showed opposite effects compared to the group on
average (Fig. 4). Levetiracetam is a broad spectrum AED
used to treat focal and generalized epilepsy and has a unique
Figure 2.
TEPs before drug intake. Grand-
averaged TEPs before intake of
placebo (PBO, blue), levetiracetam
(LEV, red), and lamotrigine (LTG,
black). The vertical line at time 0
represents the time of the TMS
stimulation. Bottom line shows
topographic distribution of surface
voltages for the most pronounced
TEPs (P25, N45, P70, N100, and
P180). Each plot shows the grand-
average across the three predrug
measurements within the
corresponding TOI and channels
within ROI (shades indicate standard
error of the mean [SEM]). For further
details, see Materials and Methods.
Epilepsia ILAE
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Figure 3.
AED-induced changes of TEPs, which were recorded before (blue) and after (red) intake of levetiracetam (LEV, left panel) and lamotrigine
(LTG, right panel). Levetiracetam and lamotrigine increased the N45 potential ipsilaterally (A, C) and suppressed the P180 component
contralaterally (B, D). Black bars underneath represent significant drug-induced changes in TEPs. T-statistic maps of the TEP amplitude
showing postdrug versus predrug differences. Blue represents increase in negativity or reduced positivity (shades indicate SEM). Each plot
shows the grand-average across significant channels, which are indicated by black dots in the t-statistic maps. For further details, see Mate-
rials and Methods.
Epilepsia ILAE
Figure 4.
Single subject data of AED effects. The change in N45 and P180 amplitude (post-pre drug, lV) has been extracted from individual subjects
from the average of significant channels in the levetiracetam and lamotrigine conditions (cf. Fig. 3). For placebo, changes in the N45 and
P180 were extracted from the average of channels within the ROI. Horizontal bars indicate group averages  SEM.
Epilepsia ILAE
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mechanism of action involving binding to SV2A vesicles,
which are widely distributed among synapses. The synaptic
vesicle protein 2 (SV2) help transportation of common con-
stituents of the vesicles, for example, calcium or adenosine
triphosphate, and controls exocytosis of vesicular neuro-
transmitters.30 Thus levetiracetam reduces neuronal
excitability and synaptic transmission of excitatory neuro-
transmitters to prevent epileptic hyperexcitability.
Lamotrigine also is a broad spectrum AED used in both
generalized and focal epilepsy, and it exerts its anticonvul-
sant effect via blockade of presynaptic voltage-gated
sodium channels to stabilize the presynaptic neuronal mem-
brane and thus reduce neurotransmitter release.31
Effects of levetiracetam and lamotrigine on N45
It has been demonstrated that the N45 component reflects
fast inhibitory postsynaptic inhibition mediated by GABAA
receptors, as positive allosteric modulators (i.e., benzodi-
azepines) increased the N45 amplitude.7 Previous research
on in vitro and in vivo models has suggested that levetirac-
etam does not act directly on GABAA receptors but works
via indirect mechanisms to increase GABAergic activity.32
Previous studies have also found that the N45 was aug-
mented only in areas contralateral to the stimulation site
with direct GABAA positive modulators.
7 However in the
current study, the effect of levetiracetam on the topography
of N45 shows a widespread negativity, suggesting that
N45 is modulated by widespread GABAAergic neuronal
pathways.
Lamotrigine does not act primarily on GABAA receptors,
and conflicting results have been reported about the activity
of lamotrigine on GABA and GABAA receptors. For
instance, lamotrigine reduced GABAA receptor–mediated
synaptic transmission in the basolateral amygdala of rats, a
brain area relevant for epileptogenesis and affective disor-
ders.33 Braga et al. speculated that lamotrigine acts at
GABAergic presynaptic terminals to reduce GABA release
by decreasing calcium influx into GABAergic terminals,
either by directly modulating voltage-gated calcium chan-
nels or by indirectly by inhibiting sodium channels. How-
ever in experiments on rat entorhinal cortex, lamotrigine
enhanced the amplitude and frequency of spontaneous
GABAA receptor–mediated inhibitory postsynaptic currents
by increasing GABA release.31 This inconsistency in obser-
vations could be due to lamotrigine action on different brain
areas. More recently it has been suggested that lamotrigine
does exert a GABAergic mechanism, as it potentiated pro-
tective effects of GABAA receptor agonists in a model of
Huntington’s disease; the authors suggested it could be act-
ing by modulation of GABA-binding sites.34
Effects of levetiracetam and lamotrigine on late latency
components
In this study, the P180 waveform was significantly lower
after the consumption of both AEDs; in addition
levetiracetam, compared to placebo, suppressed the N100
component. Generally the P180 peak has been associated
with auditory evoked activity generated by the coil click
during stimulation.35 However, this possible cofound can be
controlled by applying a masking sound throughout the
TMS session.23 Moreover, the postdrug measurements have
been obtained with the same stimulation intensity as
predrug measurements (100% RMT at predrug intake);
therefore, we exclude a connection with auditory effects.
The suppression of the N100/P180 waveform complex
has been a key finding in a previous study that involved
patients with epilepsy.9 Results have been interpreted as a
decreased inhibitory state in patients. Of interest, all patients
were treated with levetiracetam; therefore, given our
present findings, it is likely that the reduction of the N100/
P180 complex may be linked to levetiracetam-induced
modulation.
A large body of evidence showed that the N100 potential
is linked to GABAB receptor–mediated neurotransmission.
Notably, the N100 amplitude increased after the administra-
tion of the GABAB agonist baclofen, and it correlated with
the duration of the cortical silent period, a TMS-EMG mar-
ker of GABAB receptor activity.
7,8,36 Therefore, a suppres-
sion of this waveform may indicate decreased GABAB
receptor–mediated inhibition. However, this finding is in
contrast with a TMS-EMG study that showed that levetirac-
etam prolonged the cortical silent period (CSP).18 Although
it is well known that levetiracetam and lamotrigine
increased RMT, their indirect activity on GABAergic inhi-
bitory circuits still needs to be fully elucidated. Analysis of
event-related spectral perturbations (ERSPs) may provide
additional knowledge and novel candidate biomarkers to be
validated in patients.
On average, participants experienced the highest level of
sedation/fatigue with levetiracetam and the second highest
with lamotrigine; this concurs with previous work, which
found that drugs acting on GABA have the highest rate of
fatigue, followed by levetiracetam, and that those acting on
sodium channels have the lowest incidence of fatigue, that
is, lamotrigine.37 These results are also in accordance with
the blood plasma concentrations of the drugs; levetiracetam
had the highest average concentration in blood outside the
reference range, with lamotrigine averaging toward a lower
concentration for its reference range. Finally, the AEDs pre-
sent in the blood and their induced sedation were indepen-
dent from the observed modulation of TMS-EEG metrics.
Furthermore, AED-induced changes of TEPs did not corre-
late with their serum level. Hence, in agreement with previ-
ous studies, the present results indicate that TMS-EEG has
the potential to provide additional useful information, com-
pared to the AED blood level, about effects of drugs on cor-
tical excitability.17,38,39 Future studies should investigate
the relation between these TMS-EEG candidate biomarkers
and the antiepileptic activity of lamotrigine and levetirac-
etam. If results turn out to be successful, TMS-EEG may
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doi: 10.1111/epi.13599
7
TMS-EEG Fingerprints of AED Effects
develop a role as an early marker of long-term treatment
outcome. In addition, it could be integrated in early phase
screening of newly developed AEDs.
Our results showed that, despite the varying profile of
effects and regardless of the (putative) molecular targets of
the different drugs, systemically administered lamotrigine
and levetiracetam exert similar modulation of TEPs. Similar
results were obtained in studies in vitro, which showed that
different AEDs, irrespective of their molecular mecha-
nisms, can increase the excitation/inhibition balance and
reduce overall neuronal and network excitability in the rat
entorhinal cortex.40
In conclusion, TMS-EEG may identify that different
AEDs have a common pathway of therapeutic effect that
involves increased neuronal inhibition, irrespective of the
primary molecular target.
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